Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 10, 2023

SELL
$38.5 - $47.13 $17,787 - $21,774
-462 Reduced 8.79%
4,792 $217,000
Q2 2023

Jul 14, 2023

SELL
$34.73 - $43.33 $170,420 - $212,620
-4,907 Reduced 48.29%
5,254 $215,000
Q1 2023

Apr 14, 2023

SELL
$33.58 - $41.2 $52,015 - $63,818
-1,549 Reduced 13.23%
10,161 $363,000
Q4 2022

Jan 20, 2023

SELL
$37.12 - $46.52 $7,646 - $9,583
-206 Reduced 1.73%
11,710 $0
Q3 2022

Oct 20, 2022

SELL
$36.54 - $48.66 $10,085 - $13,430
-276 Reduced 2.26%
11,916 $527,000
Q2 2022

Jul 12, 2022

SELL
$31.71 - $43.0 $3,995 - $5,418
-126 Reduced 1.02%
12,192 $451,000
Q1 2022

Apr 11, 2022

SELL
$29.88 - $37.04 $96,691 - $119,861
-3,236 Reduced 20.8%
12,318 $456,000
Q4 2021

Jan 24, 2022

SELL
$25.61 - $35.1 $13,906 - $19,059
-543 Reduced 3.37%
15,554 $474,000
Q3 2021

Oct 12, 2021

BUY
$33.54 - $40.55 $3,488 - $4,217
104 Added 0.65%
16,097 $540,000
Q2 2021

Jul 19, 2021

SELL
$34.54 - $47.25 $17,719 - $24,239
-513 Reduced 3.11%
15,993 $638,000
Q1 2021

Apr 23, 2021

SELL
$42.51 - $63.78 $37,068 - $55,616
-872 Reduced 5.02%
16,506 $742,000
Q4 2020

Jan 15, 2021

SELL
$45.3 - $60.27 $34,881 - $46,407
-770 Reduced 4.24%
17,378 $982,000
Q3 2020

Oct 15, 2020

SELL
$47.45 - $62.95 $174,758 - $231,844
-3,683 Reduced 16.87%
18,148 $861,000
Q2 2020

Jul 09, 2020

BUY
$46.85 - $61.05 $163,319 - $212,820
3,486 Added 19.0%
21,831 $1.29 Million
Q1 2020

Apr 16, 2020

BUY
$41.6 - $63.4 $29,660 - $45,204
713 Added 4.04%
18,345 $867,000
Q4 2019

Jan 17, 2020

SELL
$53.85 - $65.27 $56,865 - $68,925
-1,056 Reduced 5.65%
17,632 $1.07 Million
Q3 2019

Oct 09, 2019

SELL
$59.06 - $72.15 $4,488 - $5,483
-76 Reduced 0.41%
18,688 $1.12 Million
Q2 2019

Jul 23, 2019

BUY
$62.09 - $86.14 $1.17 Million - $1.62 Million
18,764 New
18,764 $1.21 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Arden Trust CO Portfolio

Follow Arden Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arden Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Arden Trust CO with notifications on news.